Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Distinct Pseudomonas aeruginosa abundance and interaction patterns in bronchiectasis patients reveal heterogeneity influencing clinical outcomes and treatment responses, offering new avenues for personalized management.
Analysis of over 19,000 bronchiectasis patients across 30 countries reveals a graded risk increase for future exacerbations with each prior event, challenging the fixed threshold concept of frequent exacerbators and confirming consistency a
In NTM-positive bronchiectasis, lower airway dysbiosis involving Mycobacterium and oral bacteria is linked to higher NET levels and more severe disease phenotypes, suggesting that the broader airway microbiome may shape inflammation and out
A 100‑patient CT substudy from the ASPEN program found that brensocatib, especially the 25‑mg dose, reduced mucus plugging and increased healthy parenchyma at 52 weeks, providing preliminary imaging evidence that it may modify disease biolo
This article reviews a robust UK trial assessing hypertonic saline and carbocisteine in bronchiectasis, revealing no significant reduction in pulmonary exacerbations over 52 weeks, highlighting the need for continued research on mucoactive
The first international paediatric bronchiectasis registry highlights significant regional differences in causes, management, and care quality, underscoring urgent needs for harmonized standards and improved multidisciplinary support.